Gardezi Adeel, Ikram Aamer, Zaman Gohar, Satti Luqman, Ahmed Pervez, Ayyub Muhammad
Department of Microbiology, Armed Forces Institute of Pathology (AFIP), Rawalpindi.
Department of Commandant, Armed Forces Bone Marrow Transplant Centre (AFBMTC), Rawalpindi.
J Coll Physicians Surg Pak. 2017 Sep;27(9):S98-S100.
Methicillin-Resistant Coagulase-Negative Staphylococcusposes a challenging situation in healthcare settings. The spread of resistance among such organisms against major drugs is alarming as it limits the treatment options for serious infections. Traditionally, Vancomycin had remained a mainstay of treatment of Methicillin-Resistant Staphylococci. Linezolid introduction into the clinical practice was a major breakthrough since it provided orally administered treatment of Methicillin-Resistant Staphylococci. Widespread use of Linezolid has gradually turned the impending fear of emergence of resistance against this novel drug into a reality. We report first case of Linezolid-Resistant Methicillin-Resistant Staphylococcushemolyticusfrom Pakistan, isolated from a leukemic patient. The organism caused a necrotic lesion on the right forearm at cannulation site of intravenous catheter. Ooze swab yielded the pure growth of Linezolid-Resistant Methicillin-Resistant Staphylococcushemolyticus.
耐甲氧西林凝固酶阴性葡萄球菌在医疗机构中构成了具有挑战性的情况。这类微生物对主要药物的耐药性传播令人担忧，因为它限制了严重感染的治疗选择。传统上，万古霉素一直是耐甲氧西林葡萄球菌治疗的主要手段。利奈唑胺引入临床实践是一项重大突破，因为它提供了口服治疗耐甲氧西林葡萄球菌的方法。利奈唑胺的广泛使用已逐渐将对这种新型药物产生耐药性的迫在眉睫的恐惧变成了现实。我们报告了首例来自巴基斯坦的耐利奈唑胺耐甲氧西林溶血葡萄球菌，该菌株从一名白血病患者中分离出来。该微生物在静脉导管插管部位的右前臂引起了坏死性病变。渗出物拭子培养出了耐利奈唑胺耐甲氧西林溶血葡萄球菌的纯培养物。
